MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1
Neuroendocrinology · 2024
DOI: 10.1159/000533549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, 2024. Verfasst von Sida Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: MicroRNAs, Somatotrophs, Neuroendocrine Tumors, Growth Hormone-Secreting Pituitary Adenoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
Aberrant miR-320a has been reported to be involved in the tumorigenesis of several cancers. In our previous study, we identified the low expression of circulating miR-320a in patients with somatotroph pituitary neuroendocrine tumor (PitNET); however, the role of miR-320a in somatotroph PitNET proliferation is still unclear.
Methods
Cell viability and colony formation assays were used to detect the effect of miR-320a and BCAT1 on GH3 cells. TargetScan was used to identify the target genes of miR-320a. Dual-luciferase reporter gene assay was used to explore the relation between miR-320a and BCAT1. Transcriptome and proteome analyses were performed between somatotroph PitNETs and healthy controls. The expression level of miR-320a in somatotroph PitNETs were detected by RT-qPCR and Western blot. Results: miR-320a mimics inhibit cell proliferation, while miR-320a inhibitors promote cell proliferation in GH3 cells. An overlap analysis using a Venn diagram revealed that BCAT1 is the only target gene of miR-320a overexpressed in somatotroph PitNETs compared to healthy controls, as revealed by both microarray and proteomics results. A dual-luciferase reporter gene assay showed that miR-320a may bind to the BCAT1-3′UTR. The transfection of miR-320a mimics downregulated the expression and miR-320a inhibitors and upregulated the expression of BCAT1 in GH3 cells. The interference of BCAT1 expression in GH3 cells downregulated cell proliferation and growth. Pan-cancer analyses demonstrated that high BCAT1 expression often indicates a poor prognosis.
Conclusion
Our findings illustrate that miR-320a may function as a tumor suppressor and BCAT1 may promote tumor progression. miR-320a may inhibit the growth of somatotroph PitNETs by targeting BCAT1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Peking University People's Hospital, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Beijing Institute for Brain Disorders Brain Tumor Center, Beijing, China.
Zitieren
APA
Zhao, S., Li, B., Gao, H., & Zhang, Y. (2024). MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1. Neuroendocrinology. https://doi.org/10.1159/000533549
Vancouver
Zhao S, Li B, Gao H, Zhang Y. MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1. Neuroendocrinology. 2024. doi:10.1159/000533549
BibTeX
@article{Zhao2024,
author = {Zhao, Sida and Li, Bin and Gao, Hua and Zhang, Yazhuo},
title = {MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1},
journal = {Neuroendocrinology},
year = {2024},
doi = {10.1159/000533549}
}
EUVIMED